Flash FinanceUS
Market closed S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics COO Timothy Keutzer to retire effective December 31, 2026

Neutral Impact 3 of 5 leadership Written later

Spero Therapeutics announced that Chief Operating Officer Timothy Keutzer will retire effective December 31, 2026, after 11 years with the company. He is expected to serve as a consultant through approximately February 28, 2027 to support the leadership transition.

Key points

  • Timothy Keutzer, Chief Operating Officer, retires effective December 31, 2026
  • Consulting arrangement expected to run until approximately February 28, 2027, terminable by either party on fifteen days' written notice
  • Keutzer will be paid an hourly rate during the consulting period; the filing gives no dollar figure

The filing

CompanySpero Therapeutics, Inc. (SPRO)
Form8-K, current report
Filed with the SECOct 27, 2026, 5:16 PM ET
Accession number0001193125-26-434452

Items reported: 5.02 Director / Officer Change

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 27, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.